Pancreatic adenocarcinoma is the most common form of pancreatic cancer, arising from exocrine ductal cells of the pancreas. It is typically aggressive with late presentation and poor overall prognosis.
Nature Communications findings showed NR2F6 deletion revived exhausted CAR-T cells and boosted activity against solid tumors. In murine models, modified cells drove tumor regression, prolonged survival and resistance to rechallenge.
Revolution Medicines said daraxonrasib extended median survival to 13.2 months versus 6.7 months for chemotherapy in a phase 3 pancreatic cancer study. The company plans to seek FDA approval for the KRAS-targeting pill.
Daraxonrasib showed median overall survival of 13.2 months versus 6.7 months for chemotherapy in a Phase III trial in previously treated metastatic pancreatic adenocarcinoma. The once-daily pan-RAS(ON) inhibitor was generally well tolerated, and the company plans to seek FDA approval.
A study published in Science sequenced cancer-related genes in 493 cat tumor samples across 13 cancer types, revealing striking genetic similarities with human cancers and opening possibilities for shared treatments.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07594067 |
TCR1188-ABC Cells in KRAS-mutated Cancers |
NOT_YET_RECRUITING | PHASE1 |
| NCT07583771 |
A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma |
NOT_YET_RECRUITING | PHASE1 |
| NCT07573215 |
Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma |
AVAILABLE | |
| NCT07566897 |
A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors |
NOT_YET_RECRUITING | PHASE1 |
| NCT07565155 |
Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency |
NOT_YET_RECRUITING | PHASE2 |
| NCT07562152 |
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma |
RECRUITING | PHASE3 |
| NCT07547033 |
Superior Mesenteric Artery First Versus Standard Approach in Pancreaticoduodenectomy |
NOT_YET_RECRUITING | NA |
| NCT07491445 |
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma |
RECRUITING | PHASE3 |
| NCT07478523 |
FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers |
RECRUITING | PHASE2 |
| NCT06892054 |
Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma |
RECRUITING | PHASE1 |
